Low-dose aspirin may reduce risk of developing ovarian cancer, a new analysis of data collected from hundreds of thousands of women in the United States shows. The observation explains that taking low-dose aspirin is associated with a lower risk of developing ovarian cancer.
The researchers’ team found that ovarian cancer’s risk was 23 percent lower in women who reported that they had recently been frequently taking aspirin doses up to 100 milligrams. They suggested that continual use of non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) at high amount could increase a risk of developing ovarian cancer.
Published in the JAMA Oncology journal, their study was led by the Harvard T.H. Chan School of Public Health in Boston, MA. It explains that low-dose aspirin may reduce risk of developing ovarian cancer.
The American Cancer Society (ACS) had reported that around 22,240 women will develop ovarian cancer, while 14,070 will die of it.
The investigators set out a study to find out whether there’s a link between timing and patterns of analgesic use and risk of ovarian cancer. As a result, the team found that recent low-dose aspirin use was associated with a reduced risk of ovarian cancer. However, the use of low-dose aspirin for a long time was not tied to cancer risk reduction. The study revealed the suggestion that taking at least 10 tablets per week of non-aspirin NSAIDs for longer-term could be linked to a higher risk of ovarian cancer.
“Our results also highlight the need for ongoing conversations between patients and their doctors on the risks and benefits of taking low-dose aspirin,” Dr. Mollie E. Barnard notes.